Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Phase 3

Completed

• Conditions: Relapsing Remitting Multiple Sclerosis
• Interventions: Drug: simvastatin; Drug: placebo

• Registration Number: NCT00668343
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-04
• Primary Completion: 2008-03
• Study First Submitted: 2008-04-27
• Study First Submitted QC: 2008-04-28
• Study First Posted: 2008-04-29
• Study Completion: 2009-03
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-29
• Last Update Posted: 2010-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. edss<5
2. >=1 attack in last year

Exclusion Criteria

1. >2 attacks in study
2. drug complication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	simvastatin	-
2	placebo	-

Primary Outcome Measures

Name	Time	Method
attack number	1 year

Trial Locations

Locations (1)

Sanaz Ahmadi; 🇮🇷 Tehran, Iran, Islamic Republic of